Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY48.70 CNY
Change Today 0.00 / 0.00%
Volume 0.0
As of 3:05 AM 06/12/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by WALVAX BIOTECHNOLOGY CO-A (300142) in the last 6 months

Announced 06/11/15
180.00M for Shandong Shijie Biological Pharmaceutical Co, Ltd.
Merger/Acquisition

Shenzhen Derun Tianqing Investment Management Partnership (Limited Partnership) entered into agreement to acquire 15% stake in Shandong Shijie Biological Pharmaceutical Co, Ltd. from Walvax Biotechnology Co.,Ltd (SZSE:300142) for CNY 180 million on June 10, 2015. On closing, Walvax will hold 85% stake in Shandong Shijie Biological Pharmaceutical Co, Ltd. Board of Directors of Walvax Biotechnology Co.,Ltd approved the transaction.


300142's price was unchanged after the transaction was announced on 06/11/15.
Investor / Buyer
Shenzhen Derun Tianqing Investment Management Partnership (Limited Partnership)
Creditor / Lender
Walvax Biotechnology Co.,Ltd
 
Announced 04/8/15
Taizhou Jietong Tairui Pharmaceutical Technology Co., Ltd.
Merger/Acquisition

Walvax Biotechnology Co.,Ltd (SZSE:300142), Hangzhou Tigermed Consulting Co., Ltd. (SZSE:300347), Sinkiang-based equity investment company and other investors signed an equity acquisition agreement to acquire a 54% stake in Taizhou Jietong Tairui Pharmaceutical Technology Co., Ltd. from Xinjiang Tairui Equity Investment Partnership, Fu Xiaoyang and another individual on April 8, 2015. The acquisition will be made through a newly established fund with a registration capital ...
Read More


300142's price was unchanged after the transaction was announced on 04/8/15.
Investor / Buyer
Hangzhou Tigermed Consulting Co., Ltd.
Walvax Biotechnology Co.,Ltd
Creditor / Lender
Xinjiang Tairui Equity Investment Partnership
 
Announced 03/21/15
85.00M for Genor BioPharma Co., Ltd.
Merger/Acquisition

Walvax Biotechnology Co.,Ltd (SZSE:300142) agreed to acquire an additional 8.83% stake in Genor BioPharma Co., Ltd. from Wison (China) Investment Co., Ltd. for CNY 85 million on March 19, 2015. An equity transfer agreement with Wison (China) Investment Co., Ltd. will be signed. Genor Biopharma had total assets of CNY 105.74 million, total liabilities of CNY 116.22 million, net liabilities of CNY 10.48 million, revenue of CNY 0.39 million and net loss of CNY 63.58 million ...
Read More


300142's price was unchanged after the transaction was announced on 03/21/15.
Investor / Buyer
Walvax Biotechnology Co.,Ltd
Creditor / Lender
Wison (China) Investment Co., Ltd.
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
300142:CH CNY48.70 CNY 0.00

300142 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 300142.
View Industry Companies
 

Industry Analysis

300142

Industry Average

Valuation 300142 Industry Range
Price/Earnings 100.0x
Price/Sales 31.7x
Price/Book 7.9x
Price/Cash Flow 155.3x
TEV/Sales 28.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WALVAX BIOTECHNOLOGY CO-A, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.